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Although Borna disease was first recognized
in the early 1800s as a neurologic syndrome with
an infectious basis, Borna disease virus (BDV)
has only recently been characterized as the
causative agent. BDV is the prototype of a newly
recognized virus family, Bornaviridae, within the
nonsegmented negative-strand RNA viruses
(order Mononegavirales) (1,2).
The molecular biology of the virus has several
unusual aspects, including nuclear localization
for replication and transcription (3), overlap of
open reading frames and transcription units
(4,5), posttranscriptional modification of sub-
genomic RNAs (6,7), and marked conservation of
coding sequence across various animal species
and tissue culture systems (8,9). BDV replicates
at lower levels than most known viruses (10,11),
is not lytic, and persists in the nervous system
despite a vigorous immune response. In the classic
syndrome, infected animals exhibit movement and
behavior disorders (10,12,13); however, clinical
signs may be dramatic, subtle, or inapparent
depending on the integrity and intensity of the host
immune response to viral gene products (14).
Natural Infection and Transmission
Originally described as a disease of horses,
Borna disease has also been found in sheep, llamas,
ostriches, cats, and cattle (15). Because an even
larger variety of species has been infected experi-
mentally, the host range is likely to include all
warm-blooded animals; no data exist concerning
infection of species other than warm-blooded hosts.
The geographic distribution of BDV is
unknown. Natural infection has been reported only
in Central Europe, North America, and parts of
Asia (Japan and Israel). However, this apparent
geographic restriction may reflect lack of reliable
methods and reagents for diagnosis of infection or
failure to consider the possibility of BDV infection.
Recent reports of asymptomatic naturally infected
animals suggest that the virus may be even more
widespread than previously thought (16-18).
Neither the reservoir nor the mode of trans-
mission of natural infection is known. An olfactory
route for transmission has been proposed because
intranasal infection is efficient, and the olfactory
bulbs of naturally infected horses show inflam-
mation and edema early in the course of disease
(19,20). BDV nucleic acid and proteins in peri-
pheral blood mononuclear cells (PBMC) also
indicate a potential for hematogenous trans-
mission (21-28). Experimental infection of rodents
results in virus persistence and is associated
with the presence of viral gene products in saliva,
urine, and feces (28); such secreta/excreta are
important in the transmission of other pathogenic
viruses (e.g., lymphocytic choriomeningitis virus
and hantaviruses). Thus the rodent provides the
potential for both a natural reservoir and vector;
however, because natural BDV infection has not
been reported in rodents, their role in BDV
transmission to other domesticated animals and
humans remains speculative. No data concerning
vertical transmission of BDV in natural or
experimental hosts have been published.
Animal Models for BDV Pathogenesis
Borna disease in naturally infected horses
and sheep is characterized by agitated aggressive
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behavior that progresses over weeks to paralysis
and inanition (29). Because its immune-mediated
disease most closely resembles that in naturally
infected horses and sheep, the Lewis rat has been
selected as a rodent model. Rats infected as adults
exhibit hyperactivity and exaggerated startle
responses coincident with viral gene products in
limbic system neurons and infiltration of mono-
nuclear cells into the brain (13,30). The inflam-
mation recedes over several weeks, but the virus
persists and animals show stereotyped motor
behavior, dyskinesias, and dystonias associated
with distinct changes in the central nervous
system (CNS) dopamine system (12,31), as well
as decreased activity and cachexia (13). In con-
trast, rats infected as neonates have a disease
characterized by stunted growth, hyperactivity,
subtle learning disturbances, and altered taste
preferences and do not mount a cellular immune
response to the virus (32,33).
Behavioral disturbances have been reported
in experimentally infected primates: tree shrews
and rhesus monkeys. Infected tree shrews have
altered social and sexual behavior, manifested
as abnormal dominance relationships and failure
to mate (34). Infected rhesus monkeys are
initially hyperactive and subsequently become
apathetic and hypokinetic (35).
BDV and Neuropsychiatric Disease
Serology (Table 1)
Its broad host and geographic range suggests
that BDV might cause human neuropsychiatric
disease. Because the behavioral disturbances in
animals resembled those of affective disorders,
particularly bipolar depression, initial studies
investigated these disorders. The earliest work to
suggest a link between BDV and human mental
illness came from a serologic survey in 1985 of 285
patients with affective disorders in the United
States, 694 psychiatric patients in Germany, and
200 healthy controls (36). An indirect immuno-
fluorescence assay (IFA) was used to detect
antibodies reactive with a BDV-infected cell line;
sera from 12 (4.3%) patients from the United
States and four (< 1%) patients from Germany
were immunoreactive; no sera from controls were
immunoreactive. Sera from many of these patients
were subsequently analyzed by a Western
immunoblot assay based on BDV nucleoprotein
(N) and phosphoprotein (P) purified by affinity
chromatography from infected rabbit kidney cells
(37). In this study of 138 patients with affective
disorders and 117 healthy controls, antibodies to
N were found in 53 (38%) patients versus 19
(16%) controls; antibodies to P were found in 16
(12%) patients versus five (4%) controls; anti-
bodies to both proteins were found in nine (6.5%)
patients versus one (< 1%) control.
Table 1. Serum immunoreactivity to Borna disease virus
 in various diseases
Disease Prevalence Assay Ref.
Disease (%) Controls (%)
Psychiatric    (4/694)   0.6   (0/200)   0 IFA (36)
(various)   (13/642)   2 (11/540)   2 IFA (60)
(200-350/   4-7      (10/   1 WB/ (61)
      5000)     1000) IFA
    (18/60) 30   (1/100)   1 WB (24,
 25)
  (18/132) 13.6   (3/203)   1.5 WB (27)
    (13/55) 23.6     (4/36) 11.1 IFA (51)
      (6/49) 12.2 IFA (38)
Affective   (12/265)   4.5   (0/105)   0 IFA (62)
  (12/285)   4.2   (0/200)   0 IFA (36)
  (53/138) 38 (19/117) 16 WB (37)
      (6/52) 11.5   (3/203)   1.4 WB (27)
    (10/27) 37 IFA (38)
Schizo-     (29/90) 32     (4/20) 20 WB (43)
phrenia
  (16/114) 14   (3/203)   1.5 WB (27)
        (1/4) 25 IFA (38)
CFS       (6/25) 24 WB (26)
MS   (15/114) 13 (10/483)   2.1 IP/ (63)
IFA
HIV-   (36/460)   7.8 (11/540)   2 IFA (60)
positive
HIV-early   (61/751)   8.1 (10/483)    2 IP/ (61)
IFA
HIV-LAP   (34/244) 14 (10/483)    2 IP/ (63)
IFA
Schisto/   (19/193)   9.8 (10/483)   2 IP/ (63)
malaria IFA
Abbreviations: IFA, immunofluorescence assay; WB, Western
immunoblot; IP, immunoprecipitation; CFS, chronic fatigue
syndrome; MS, multiple sclerosis; HIV, human immunodefi-
ciency virus; LAP, lymphadenopathy; Schisto/malaria, schisto-
somiasis or malaria.
To establish a correlation between
immunoreactivity to BDV and the duration and
severity of psychiatric disease, Bode et al.
performed IFA on multiple serum samples taken
at  different times from 71 patients with various
diagnoses including minor or major depression,
paranoid psychosis, schizophrenia, anxiety
disorder, and personality disorder (38). Overall,
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greater than 20%, a marked increase from the 2%
to 4% found in an earlier study that assayed
specimens from each patient at one time. Thirty-
seven percent of patients with major depression,
25% with paranoid psychosis, and only 6% or
fewer with reactive depression and other
neurotic conditions were seropositive by day 17 of
illness. Because BDV gene products have been
identified in PBMC of infected rats (28), PBMC
from patients with neuropsychiatric diseases
were examined for viral antigens by fluorescence
activated cell sorting analysis (39). Of the 70
patients tested, more than 40% were antigen
carriers, twice the number predicted by the
previous serologic survey.
Some similarities between particular animal
models of BDV infection and schizophrenia have
been reported. The subtle signs of disease caused
by infection in neonatal rats (e.g., learning
deficiencies, hyperactivity with CNS abnor-
malities including cerebellar disorganization and
loss of dentate gyrus granule cells [32,33,40,41])
are consistent with a longstanding hypothesis
that schizophrenia reflects an early brain insult
(e.g., infection) resulting in abnormal brain
development (42) and prompted investigation of
the role of BDV infection in the pathogenesis of
schizophrenia (43). A Western immunoblot assay
based on BDV N, P, and matrix protein (M)
purified from infected human neuroblastoma
cells was used to examine sera from 90 schizo-
phrenic patients and 20 healthy controls.
Antibodies to one BDV protein (N, P, or M) were
detected in 29 (32%) patients and four (20%)
controls. Antibodies to two or more BDV proteins
were detected in 13 (14.4%) patients and zero
controls. Antibodies to M protein were found in
12 (13.3%) patients and zero controls. Immuno-
reactivity to two or more BDV proteins or M pro-
tein was significantly associated with abnormal
brain morphology in magnetic resonance image
analysis (MRI) and the clinical diagnosis of de-
ficit syndrome (a schizophrenia subgroup charac-
terized by social withdrawal, neurologic dysfunc-
tion, and neuroanatomic abnormalities). Similar
findings indicated an association between antibodies
reactive with BDV proteins and MRI evidence of
cerebral atrophy in schizophrenic patients (44).
Molecular Epidemiology (Table 2)
Interest in the potential role of BDV as a
human pathogen and in BDV-infected animals as
models for human neuropsychiatric diseases
guided efforts to identify the infectious agent.
Because of low viral productivity and tight asso-
ciation of BDV with plasma membranes, classic
methods for virus isolation have been unsuc-
cessful; however, BDV nucleic acids have been
independently cloned from horse isolates by using a
purely molecular subtractive cloning approach
(45,46). The viral genome was subsequently cloned
from viral particles (4) and nuclear extracts of
infected cells (47). With the advent of viral
sequence information, new diagnostic reagents
Table 2. Borna disease virus nucleic acid in patients with various diseases
Disease Tissue Prevalence Divergence* Ref.
Disease (%) Controls (%)
Psychiatric PBMC     (4/6) 66.7   (0/10)   0      0-3.6       (22)
 (various) PBMC   (5/12) 41.7   (0/23)   0      0-4       (27)
PBMC (22/60) 37 (8/172)   4.7 (24, 25)
PBMC-coculture   (3/32)   9.4     (0/5)   0 0.07-0.83 (23, 53)
Affective PBMC     (1/3) 33.3   (0/23)   0       (27)
PBMC     (1/6) 16.7   (0/36)   0       (51)
PBMC     (0/9)   0       (56)
Schizophrenia PBMC   (7/11) 63.6   (0/23)   0       (27)
PBMC   (5/49) 10.2   (0/36)   0       (51)
PBMC 4.2-9.3       (54)
Brain     (0/3)   0     (0/3)   0       (55)
CSF   (0/48)   0     (0/9)   0       (55)
PBMC     (0/9)   0     (0/9)   0       (55)
PBMC   (0/26)   0       (56)
CFS PBMC   (3/25) 12 6.0-14       (26)
Hippocampal sclerosis Brain     (4/5) 80       (53)
Abbreviations: PBMC, peripheral blood mononuclear cells; CSF, cerebrospinal fluid; CFS, chronic fatigue syndrome.
*Divergence of P-gene nucleotide sequence from common BDV isolates (strain V [4] and He/80 [9]).132 Emerging Infectious Diseases Vol. 3, No. 2, April–June 1997
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for BDV infection have been introduced,
including recombinant proteins for serology as
well as oligonucleotide primers and probes for
molecular epidemiology.
The earliest experiments in BDV molecular
epidemiology examined whether conserved virus
sequences could be identified across several host
species. Reverse transcription polymerase chain
reaction (RT-PCR), as well as extensive experi-
mental passage through rabbit and rat brains
and cell lines from various species, was used to
amplify and clone coding and noncoding sequences
from virus strains divergent by over 50 years’
growth in nature. Because of inaccuracies in viral
RNA-dependent RNA polymerases, most single-
stranded RNA viruses have sequence divergence
of 103 to 104 per site per round of replication (48-
50). Sequence analysis of BDV isolates showed a
much lower rate of divergence. For N and P
sequences, maximum variability was 4.1% at the
nucleotide level and 1.5% at the predicted amino
acid level (8). Similar sequence conservation was
later found for sequences from naturally infected
donkeys, sheep, and cats (9, H. Ludwig, pers.
comm.). The extent to which sequence con-
servation in BDV represents enhanced polymerase
fidelity, or more likely, selective environmen-
tal pressures  is unknown.
Extending molecular analysis to human
materials is both complex and controversial. If
BDV infects neuropsychiatric disease patients,
viral nucleic acids are present at lower concen-
trations in human brain and PBMC than in
previously studied naturally or experimentally
infected hosts because investigators who report
isolation of BDV nucleic acid from human PBMC
must use the highly sensitive technique of nested
RT-PCR. Groups in Germany and Japan have
detected viral nucleic acid in PBMC of patients
with neuropsychiatric diseases: Bode and colleagues
found BDV nucleic acids in four (66.7%) of six
patients (22); Sauder and colleagues found BDV
sequences in 13 (50%) of 26 neuropsychiatric
patients (seven patients with schizophrenia, one
with affective disorder, and five with other
psychiatric disorders) (27); Kishi and co-workers
found BDV nucleic acids in PBMC of 22 (37%) out
of 60 neuropsychiatric patients (24) and eight
(4.7%) out of 172 blood donor controls (25); Igata-
Yi et al. detected BDV nucleic acids in six (10.9%)
of 55 neuropsychiatric patients (five patients
with schizophrenia, one with depression) versus
zero of 36 blood donor controls (51); and Nakaya
et al. reported BDV nucleic acid in three (12%) of
25 chronic fatigue syndrome patients (26). Addi-
tionally, BDV nucleic acids and immunoreactivity
have been detected in the hippocampus of four of
five North American patients with postmortem
diagnosis of hippocampal sclerosis (52).
Genomic analyses of BDV isolates from human
patients have yielded differing estimates of
nucleotide sequence conservation (Table 2).
Extensive conservation of the N and P open
reading frames, consistent with previous findings
in field and tissue culture isolates (8), has been
reported (22,27). Infectious BDV has been isolated
after cocultivation of PBMC from neuropsychiatric
patients with a human oligodendroglial cell line
(23). Sequences of these isolates were highly
conserved with previously identified sequences
(53); other groups have described greater
sequence divergence (26,54). However, differences
in levels of sequence conservation may reflect
variations in methods for RT-PCR amplification
rather than true strain differences (27).
In two reports RT-PCR did not yield evidence
of BDV nucleic acid in neuropsychiatric disease
patients (Table 2): No BDV nucleic acid was
found by RT-PCR analysis of brain tissue, cere-
brospinal fluid, or PBMC from patients with
schizophrenia (55); similarly, no BDV nucleic
acid was found in RT-PCR studies of PBMC from
26 patients with schizophrenia and nine with
affective disorders (56).
Special Considerations for BDV Diagnostics
Although a wide variety of assays (IFA,
Western immunoblot, radioimmunoprecipitation,
and enzyme-linked immunosorbent assay) and
antigen preparations (infected cells, infected cell
extracts, and recombinant proteins produced in
prokaryotic or baculovirus systems) have been
used for BDV serology, generally accepted stan-
dards for diagnosis of human BDV infection have
not been established. Because only limited data
concerning interassay comparability for serology
within individual laboratories (and none between
different laboratories) have been established, dis-
crepancies between investigators may reflect
differences in clinical populations, assay sen-
sitivity, or other factors.
Similarly, agreement concerning methods for
molecular diagnosis of BDV infection is limited.
Most investigators use RT-PCR; some use a
method sensitive to 100 to 300 copies of RNA
template (nested RT-PCR, 80 to 100 cycles),133 Vol. 3, No. 2, April–June 1997 Emerging Infectious Diseases
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while others use less sensitive methods (no
nesting, 30 cycles). Only investigators using the
more sensitive method have reported BDV gene
products in human materials (PBMC, brain).
RT-PCR, particularly nested RT-PCR, is
prone to artifacts because of inadvertent intro-
duction of template from laboratory isolates or
cross-contamination of samples. Because putative
human isolates detected by nested RT-PCR are
similar in sequence to known animal and tissue
culture isolates, it has been argued that they
represent low-level contaminants. However, the
finding of sequence conservation is consistent
with previous analyses of well-characterized
isolates disparate by host species and geography
(8,9) and cannot be used to discount the validity
of positive nested RT-PCR results.
Future Directions
The broad potential host range of BDV
suggests that humans are targets for infection.
Rodents with persistent BDV infection and
minimal overt signs of disease and domestic
animals and livestock could serve as vectors.
Serum antibodies reactive with BDV have been
detected in asymptomatic farmworkers exposed
to ostriches with a Borna disease-like syndrome
(57). Immunoreactivity to BDV and neurologic
disturbances have been reported in a farm
worker exposed to seropositive asymptomatic
horses and sheep (58). Finally, although no
human cases of disease have been linked to feline
infection, there is evidence of BDV infection in
house cats in Europe (59) and Japan (18).
However, even though BDV could infect humans
and is likely to do so, a number of questions
remain unanswered: The sources and routes of
potential human infection are not clear, no
detailed epidemiology has been done in animal
populations, and transmission from domestic
animals to humans has not been demonstrated.
Viral gene products are readily detected in
CNS of natural and experimental hosts without
such sensitive methods as nested RT-PCR. The
need to use sensitive methods to detect BDV
nucleic acid in humans indicates that the virus is
present only at low levels. Thus, if BDV can be
implicated as a factor in human neuropsychiatric
disease, mechanisms for pathogenesis may be
different from those found in other natural and
experimental hosts. Although a higher prevalence
of markers for BDV infection has been reported
in neuropsychiatric patients than in controls,
no single neuropsychiatric disease has been
correlated with BDV infection. Efforts to link
BDV with neuropsychiatric disease have not
used accepted epidemiology standards.
To rigorously address the issues of BDV epi-
demiology and pathogenesis, multicenter groups in
Europe and the United States are collaborating
to collect and perform blinded analysis of human
clinical materials by standardized methods and
reagents. The objectives of these projects will be
to determine the prevalence of serum antibodies
to BDV in patients and controls and the extent to
which various assays for antibodies are in accord,
the prevalence of BDV nucleic acids in brains and
PBMC of patients and controls, and the corre-
lation between antibodies to BDV or viral nucleic
acids and a particular neuropsychiatric disease.
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